CCA CATO Associate Protocol Development & Study Design 2 — Questions and Answers
Question 1: What is the role of the Statistical Analysis Plan (SAP) in clinical trial protocol development?
- To recruit participants at investigative sites
- To pre-specify statistical methods and analyses before unblinding (Correct answer)
- To document adverse events during the trial
- To outline the regulatory submission timeline
Correct answer: To pre-specify statistical methods and analyses before unblinding
The SAP is finalized before database lock and unblinding to pre-specify all statistical methods, preventing post-hoc manipulation of analyses that could bias results.
Question 2: What does 'sample size calculation' in a clinical protocol primarily determine?
- The number of sites needed for the study
- The minimum number of participants needed to detect a meaningful treatment effect (Correct answer)
- The duration of the follow-up period
- The number of protocol amendments allowed
Correct answer: The minimum number of participants needed to detect a meaningful treatment effect
Sample size calculations ensure the study has adequate statistical power to detect a clinically meaningful difference between treatment arms, if one truly exists.
Question 3: In a crossover study design, what distinguishes it from a parallel group design?
- Participants are assigned to multiple sites
- Each participant receives more than one treatment in sequence (Correct answer)
- There is no control group
- Blinding is not possible
Correct answer: Each participant receives more than one treatment in sequence
In a crossover design, each participant receives multiple treatments in different periods, allowing each person to serve as their own control and reducing inter-subject variability.
Question 4: Which ICH guideline provides the foundational framework for the design, conduct, recording, and reporting of clinical trials?
- ICH E3
- ICH E6(R2) (Correct answer)
- ICH E9
- ICH E2A
Correct answer: ICH E6(R2)
ICH E6(R2) is the Good Clinical Practice (GCP) guideline that establishes international standards for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials.
Question 5: What is the 'washout period' in a clinical trial protocol?
- The time between screening and randomization
- A period between treatment phases during which a prior treatment is cleared from the body (Correct answer)
- The duration of the study follow-up
- The time required to train site staff
Correct answer: A period between treatment phases during which a prior treatment is cleared from the body
A washout period in crossover or sequential studies allows previously administered treatments to be eliminated from the body before the next treatment is started, preventing carryover effects.
Question 6: Which element is essential for ensuring the protocol clearly defines what constitutes the primary endpoint?
- List of excluded medications
- Operational definition including measurement method, timing, and assessor (Correct answer)
- IRB contact information
- Site feasibility criteria
Correct answer: Operational definition including measurement method, timing, and assessor
A primary endpoint must be precisely operationalized with a clear measurement method, the time point of assessment, and who performs the assessment to ensure consistent data collection.
Question 7: What is an adaptive clinical trial design?
- A design that does not require randomization
- A design that allows pre-specified modifications to the trial based on interim data (Correct answer)
- A design used exclusively in Phase I studies
- A design that uses historical controls instead of a placebo group
Correct answer: A design that allows pre-specified modifications to the trial based on interim data
Adaptive designs permit pre-specified, data-driven modifications to study parameters (such as sample size or dose) during the trial while maintaining scientific validity and controlling the type I error rate.
CCA CATO Associate Protocol Development & Study Design 2
What is the role of the Statistical Analysis Plan (SAP) in clinical trial protocol development?